Lazard Asset Management LLC acquired a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA – Free Report) during the first quarter, HoldingsChannel.com reports. The firm acquired 72,395 shares of the company’s stock, valued at approximately $1,265,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in USNA. Nantahala Capital Management LLC purchased a new stake in USANA Health Sciences in the 4th quarter valued at $11,485,000. Millennium Management LLC raised its holdings in shares of USANA Health Sciences by 715.7% during the 4th quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock worth $5,603,000 after acquiring an additional 250,424 shares during the period. Two Sigma Investments LP boosted its position in shares of USANA Health Sciences by 349.8% during the 3rd quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock valued at $4,434,000 after acquiring an additional 125,158 shares during the last quarter. UBS Group AG boosted its position in shares of USANA Health Sciences by 252.3% during the 4th quarter. UBS Group AG now owns 138,334 shares of the company’s stock valued at $2,715,000 after acquiring an additional 99,063 shares during the last quarter. Finally, Tudor Investment Corp ET AL grew its holdings in shares of USANA Health Sciences by 354.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock valued at $2,153,000 after purchasing an additional 85,570 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.
Insider Activity at USANA Health Sciences
In other USANA Health Sciences news, Director John Turman Fleming sold 2,450 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $17.93, for a total value of $43,928.50. Following the transaction, the director owned 4,230 shares of the company’s stock, valued at $75,843.90. This represents a 36.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Joshua Foukas sold 3,791 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $19.82, for a total transaction of $75,137.62. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 17,660 shares of company stock worth $336,579. 0.82% of the stock is owned by corporate insiders.
USANA Health Sciences Stock Up 0.2%
USANA Health Sciences (NYSE:USNA – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). The business had revenue of $223.27 million for the quarter, compared to analysts’ expectations of $235.00 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. Sell-side analysts anticipate that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Finally, Zacks Research downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.
View Our Latest Report on USANA Health Sciences
USANA Health Sciences Company Profile
USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.
Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.
Read More
- Five stocks we like better than USANA Health Sciences
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA – Free Report).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
-USDTB.png){kind=small}
